Historical position

BlackRock, Inc.’s Bio-Techne Corp (TECH) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

BlackRock, Inc.Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2018Earliest verified positive filing snapshot
Latest statusHistorical positionBased on the latest supported relationship state
Peak shares5.23MHighest verified quarter-end share count
Quarters reported9Verified quarters with shares above zero
What happened?

BlackRock, Inc. first reported Bio-Techne Corp in Q3 2018. The reported position was increased and reduced across later filings. Verified positive position history runs through Q3 2022. The current relationship status cannot be determined reliably from supported data.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2022
Bought 0.9% more+38.66K shares · 4.33M shares reported after the change
Filing context

Quarter-end price $284.00

Q1 2022
Bought 1.7% more+75.48K shares · 4.40M shares reported after the change
Filing context

Quarter-end price $433.04

Q4 2021
Sold 0.5% of the position−23.94K shares · 4.33M shares remained
Filing context

Quarter-end price $517.34

Q3 2021
Sold 16.8% of the position−876.44K shares · 4.35M shares remained
Filing context

Quarter-end price $484.57

Q2 2021
Bought 14.3% more+654.08K shares · 5.23M shares reported after the change
Filing context

Quarter-end price $450.26

Q1 2021
Bought 5.2% more+226.56K shares · 4.57M shares reported after the change
Filing context

Quarter-end price $381.93

Portfolio importance

How important was Bio-Techne Corp in BlackRock, Inc.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.0%Q3 2022
Last reported rank#419Rank unavailable
Peak portfolio weight0.1%Q2 2021
Best historical rank#293Q2 2021
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$72.472026-09-21

Market context only; not an investor transaction price.

Latest filing quarter-end price$284.00Q3 2022

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-07
Open SEC filing ↗

Coverage is bounded to BlackRock’s top reported positions and material events rather than every security in each Form 13F. Source filings may contain additional securities, and 13F filings do not reveal exact trade dates or execution prices.